TIM-3, a promising target for cancer immunotherapy
Open accessAbstract
Patients with malignant tumor treated with immunotherapy have received significant clinical benefits over the years. Immune checkpoint blocking agents, such as anti-cytotoxic T-lymphocyte-associated protein-4 (anti-CTLA-4) and anti-programmed cell death protein-1 (anti-PD-1) monoclonal antibodies, have produced impressive clinical results in different types of cancer. T-cell immunoglobulin and mucin domain-3 (TIM-3), another immune checkpoint, could inhibit cancer immunity. Recent studies have highlighted that TIM-3 has an important role to play in T-cell exhaustion and correlates with the outcome of anti-PD-1 therapy. Targeting TIM-3 might be a promising approach for cancer immunotherapy. Here, we review the role of TIM-3 in cancer and clinical trials with TIM-3 inhibitors.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Combining PD-1 and TIM-3 blockade might offer improved outcomes in overcoming resistance to anti-PD-1 therapy.
“Consequently, combining PD-1 and TIM-3 blockade might offer improved outcomes in overcoming resistance to anti-PD-1 therapy [59].”
From The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors (2024) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
2 retracted
Tim-3 Expression in Cervical Cancer Promotes Tumor Metastasis
Cao, Y., Zhou, X., Huang, X., Li, Q., Gao, L., Jiang, L., Huang, M. J., & Zhou, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053834 · Cited by 144 · see citing works
RetractedAnalysis of Tim-3 as a therapeutic target in prostate cancer
Piao, Y.-R., Jin, Z., Yuan, K., & Jin, X. (2014) · Tumor Biology · doi:10.1007/s13277-014-2464-1 · Cited by 38 · see citing works
RetractedAdverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157 · see citing works
Rittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,684 · see citing works
Weber, J. S., D’Angelo, S. P., Minor, D. R., Hodi, F. S., Gutzmer, R., Neyns, B., Höeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676 · see citing works
Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096 · see citing works
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072 · see citing works
Monney, L., Sabatos, C. A., Gaglia, J. L., Ryu, A., Waldner, H., Chernova, T., Manning, S., Greenfield, E. A., Coyle, A. J., Sobel, R. A., et al. (2002) · Nature · doi:10.1038/415536a · Cited by 1,648 · see citing works
Koyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., Gandhi, L., Redig, A. J., Rodig, S. J., Asahina, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms10501 · Cited by 1,580 · see citing works
Fourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100637 · Cited by 1,307 · see citing works
Hellmann, M. D., Rizvi, N. A., Goldman, J. W., Gettinger, S. N., Borghaei, H., Brahmer, J. R., Ready, N. E., Gerber, D. E., Chow, L. Q., Juergens, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30624-6 · Cited by 962 · see citing works
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Valsecchi, M. E. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1509660 · Cited by 874 · see citing works
Chiba, S., Baghdadi, M., Akiba, H., Yoshiyama, H., Kinoshita, I., Dosaka-Akita, H., Fujioka, Y., Ohba, Y., Gorman, J. V., Colgan, J. D., et al. (2012) · Nature Immunology · doi:10.1038/ni.2376 · Cited by 838 · see citing works
Zhou, Q., Munger, M. E., Veenstra, R. G., Weigel, B. J., Hirashima, M., Munn, D. H., Murphy, W. J., Azuma, M., Anderson, A. C., Kuchroo, V. K., et al. (2011) · Blood · doi:10.1182/blood-2010-10-310425 · Cited by 675 · see citing works
Freeman, G. J., Casasnovas, J. M., Umetsu, D. T., & DeKruyff, R. H. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2010.00903.x · Cited by 613 · see citing works
Ngiow, S. F., von Scheidt, B., Akiba, H., Yagita∥, H., Teng, M. W. L., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0096 · Cited by 575 · see citing works
Zhou, G., Sprengers, D., Boor, P. P. C., Doukas, M., Schutz, H. M., Mancham, S., Pedroza‐González, A., Polak, W. G., de Jonge, J., Gaspersz, M. P., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.017 · Cited by 412 · see citing works
Gao, X., Zhu, Y., Li, G., Huang, H., Zhang, G., Fengming, W., Sun, J., Yang, Q., Zhang, X., & Lu, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030676 · Cited by 406 · see citing works
Thommen, D. S., Schreiner, J., Müller, P., Herzig, P., Roller, A., Belousov, A., Umaña, P., Pisa, P., Klein, C., Bacac, M., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0097 · Cited by 395 · see citing works
Yang, Z., Grote, D. M., Ziesmer, S. C., Niki, T., Hirashima, M., Novak, A. J., Witzig, T. E., & Ansell, S. M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59806 · Cited by 309 · see citing works
Jie, H.-B., Gildener‐Leapman, N., Li, J., Srivastava, R. M., Gibson, S. P., Whiteside, T. L., & Ferris, R. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.645 · Cited by 285 · see citing works
Phosphotyrosine-Dependent Coupling of Tim-3 to T-Cell Receptor Signaling Pathways
Lee, J., Su, E. W., Zhu, C., Hainline, S., Phuah, J., Moroco, J. A., Smithgall, T. E., Kuchroo, V. K., & Kane, L. P. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05297-11 · Cited by 285 · see citing works
Silva, I. G., Yasinska, I. M., Sakhnevych, S. S., Fiedler, W., Wellbrock, J., Bardelli, M., Varani, L., Hussain, R., Siligardi, G., Ceccone, G., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.07.018 · Cited by 236 · see citing works
Cao, E., Zang, X., Ramagopal, U. A., Mukhopadhaya, A., Fedorov, A. A., Fedorov, E. V., Zencheck, W. D., Lary, J. W., Cole, J. L., Deng, H., et al. (2007) · Immunity · doi:10.1016/j.immuni.2007.01.016 · Cited by 228 · see citing works
Xu, L., Huang, Y., Tan, L., Yu, W., Chen, D., Lu, C., He, J.-Y., Wu, G., Liu, X., & Zhang, Y. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.09.017 · Cited by 215 · see citing works
Fourcade, J. J., Sun, Z., Pagliano, O., Chauvin, J.-M., Sander, C., Janjic, B. M., Tarhini, A. A., Tawbi, H. A., Kirkwood, J. M., Moschos, S. J., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-2908 · Cited by 209 · see citing works
An IL-27/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction
Zhu, C. Y., Sakuishi, K., Xiao, S., Sun, Z., Zaghouani, S., Gu, G., Wang, C., Tan, D. J., Wu, C., Rangachari, M., et al. (2015) · Nature Communications · doi:10.1038/ncomms7072 · Cited by 203 · see citing works
Tim-3 Expression Defines Regulatory T Cells in Human Tumors
Yan, J., Zhang, Y., Zhang, J., Liang, J., Li, L., & Zheng, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058006 · Cited by 183 · see citing works
Decreased Galectin-9 and Increased Tim-3 Expression Are Related to Poor Prognosis in Gastric Cancer
Jiang, J., Jin, M., Kong, F., Cao, D., Ma, H., Jia, Z., Wang, Y., Suo, J., & Cao, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081799 · Cited by 172 · see citing works
Too Much of a Good Thing? Tim-3 and TCR Signaling in T Cell Exhaustion
Ferris, R. L., Lu, B., & Kane, L. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400557 · Cited by 169 · see citing works
Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer
Kang, C.-W., Dutta, A., Chang, L.-Y., Mahalingam, J., Lin, Y., Chiang, J., Hsu, C.-Y., Huang, C., Su, W., Chu, Y., et al. (2015) · Scientific Reports · doi:10.1038/srep15659 · Cited by 162 · see citing works
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apétoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.201006432011512c · Cited by 131 · see citing works
Liu, J., Zhang, S., Hu, Y., Yang, Z., Li, J. P., Liu, X., Deng, L., Wang, Y., Zhang, X., Jiang, T., et al. (2016) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000122 · Cited by 127 · see citing works
Komohara, Y., Morita, T., Annan, D. A., Horlad, H., Ohnishi, K., Yamada, S., Nakayama, T., Kitada, S., Suzu, S., Kinoshita, I., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0156 · Cited by 116 · see citing works
Tim-3 enhances FcεRI-proximal signaling to modulate mast cell activation
Phong, B. L., Avery, L., Sumpter, T. L., Gorman, J. V., Watkins, S. C., Colgan, J. D., & Kane, L. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20150388 · Cited by 108 · see citing works
Liu, Z., Han, H., He, X., Li, S., Wu, C., Yu, C., & Wang, S. (2016) · Oncology Letters · doi:10.3892/ol.2016.4142 · Cited by 101 · see citing works
Guo, Z., Cheng, D., Xia, Z., Luan, M., Wu, L., Wang, G., & Zhang, S. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-215 · Cited by 94 · see citing works
Xu, L., Yang, L., Yao, D., Wu, X., Li, J., Liu, X., Deng, L., Huang, C., Wang, Y., Li, D., et al. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.01.001 · Cited by 92 · see citing works
The T-cell immunoglobulin and mucin domain (Tim) gene family in asthma, allergy, and autoimmunity
Li, Z., Ju, Z., & Frieri, M. (2013) · Allergy and Asthma Proceedings · doi:10.2500/aap.2013.34.3646 · Cited by 88 · see citing works
Up-regulation of Tim-3 is associated with poor prognosis of patients with colon cancer.
Zhou, E., Huang, Q. B., Wang, J., Fang, C., Yang, L., Zhu, M., Chen, J., Chen, L., & Dong, M. (2015) · PubMed Central · Cited by 85 · see citing works
Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer
Xu, B., Yuan, L., Gao, Q., Yuan, P., Zhao, P., Yuan, H., Fan, H., Li, T., Qin, P., Han, L., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4112 · Cited by 80 · see citing works
The Clinical Significance of Abnormal Tim-3 Expression on NK Cells from Patients with Gastric Cancer
Wang, Z., Zhu, J., Gu, H., Yuan, Y., Zhang, B., Zhu, D., Zhou, J., Zhu, Y., & Chen, W. (2015) · Immunological Investigations · doi:10.3109/08820139.2015.1052145 · Cited by 79 · see citing works
Tim-3 is upregulated in human colorectal carcinoma and associated with tumor progression
Yu, M., Bin, L., Liu, Y., Me, Y., Wang, L., & Zhang, P. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.6065 · Cited by 69 · see citing works
Tim-3 expression represents dysfunctional tumor infiltrating T cells in renal cell carcinoma
Cai, C., Xu, Y., Wu, Z., Dong, Q., Li, M.-Y., Olson, J. C., Rabinowitz, Y. M., Wang, L., & Sun, Y. (2015) · World Journal of Urology · doi:10.1007/s00345-015-1656-7 · Cited by 64 · see citing works
TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells
Kikushige, Y., & Miyamoto, T. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1433-6 · Cited by 60 · see citing works
Expression of Tim-3 in gastric cancer tissue and its relationship with prognosis.
Cheng, G., Li, M., Wu, J., Ji, M., Cheng, F., Shi, H., Zhu, D., Chen, L., Zhao, J., Shi, L., et al. (2015) · PubMed Central · Cited by 57 · see citing works
Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas
Baghdadi, M., Nagao, H., Yoshiyama, H., Akiba, H., Yagita∥, H., Dosaka‐Akita, H., & Jinushi, M. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1371-9 · Cited by 56 · see citing works
Tim-3 and Tim-4 as the potential targets for antitumor therapy
Cheng, L., & Ruan, Z. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1056953 · Cited by 53 · see citing works
An increased number of PD-1+ and Tim-3+ CD8+ T cells is involved in immune evasion in gastric cancer
Takano, S., Saito, H., & Ikeguchi, M. (2016) · Surgery Today · doi:10.1007/s00595-016-1305-9 · Cited by 42 · see citing works
The Expression of Tim-3 in Peripheral Blood of Ovarian Cancer
Wu, J., Liu, C., Shao, Q., & Hou, H. (2013) · DNA and Cell Biology · doi:10.1089/dna.2013.2116 · Cited by 41 · see citing works
Arai, Y., Saito, H., & Ikeguchi, M. (2012) · Europe PMC (PubMed Central) · Cited by 41 · see citing works
荒井, 陽. (2012) · Tottori University research result repository (Tottori University) · Cited by 29 · see citing works
Analysis of Tim-3 as a therapeutic target in prostate cancer
Piao, Y.-R., & Jin, X. (2017) · Tumor Biology · doi:10.1177/1010428317716628 · Cited by 28 · see citing works
Xu, L., Chen, D., He, J.-Y., Lu, C., Liu, X., Le, H., Wang, C.-Y., & Zhang, Y. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.22.9945 · Cited by 20 · see citing works
Tim Protein Structures Reveal a Unique Face for Ligand Binding
Anderson, A. C., Xiao, S., & Kuchroo, V. K. (2007) · Immunity · doi:10.1016/j.immuni.2007.03.004 · Cited by 16 · see citing works
Correction: CheckMate for advanced-stage ccRCC? Nivolumab and cabozantinib aMETEORate poor survival
Thoma, C. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.207 · Cited by 6 · see citing works
CheckMate for advanced-stage ccRCC? Nivolumab and cabozantinib aMETEORate poor survival
Thoma, C. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.246 · Cited by 5 · see citing works
CheckMate for advanced-stage ccRCC? Nivolumab and cabozantinib aMETEORate poor survival
Thoma, C. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.178 · Cited by 3 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [52]Zhou G Sprengers D Boor PPC Antibodies Against Immune Checkpoint Molecules RestoreFunctions of Tumor-Infiltrating T Cells in HepatocellularCarcinomas Gastroenterology 2017 153 4 1107.e10 1119 28648905
Cited by
Sorted by citations
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Qin, S., Xu, L., Yi, M., Yu, S., Wu, K., & Luo, S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1091-2 · Cited by 1,145 · see citing works
Next generation of immune checkpoint inhibitors and beyond
Marin-Acevedo, J. A., Kimbrough, E. O., & Lou, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01056-8 · Cited by 560 · see citing works
NK Cell-Based Immune Checkpoint Inhibition
Khan, M. B., Arooj, S., & Wang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00167 · Cited by 359 · see citing works
Signaling pathways and therapeutic interventions in gastric cancer
Lei, Z., Teng, Q., Qin, T. L., Chen, W., Xie, Y., Wu, K., Zeng, Q., Zeng, L., Pan, Y., Chen, Z., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01190-w · Cited by 325 · see citing works
Self-citationThe yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity
Schnell, A., Bod, L., Madi, A., & Kuchroo, V. K. (2020) · Cell Research · doi:10.1038/s41422-020-0277-x · Cited by 223 · see citing works
A comprehensive review of immune checkpoint inhibitors for cancer treatment
Hossain, M. A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113365 · Cited by 196 · see citing works
Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy
Cao, Y., Wang, X., Jin, T., Tian, Y., Dai, C., Widarma, C., Song, R., & Xu, F. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00348-8 · Cited by 184 · see citing works
The 6th R of Radiobiology: Reactivation of Anti-Tumor Immune Response
Boustani, J., Grapin, M., Laurent, P.-A., Apétoh, L., & Mirjolet, C. (2019) · Cancers · doi:10.3390/cancers11060860 · Cited by 162 · see citing works
Tim-3: A co-receptor with diverse roles in T cell exhaustion and tolerance
Tang, R., Rangachari, M., & Kuchroo, V. K. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101302 · Cited by 155 · see citing works
Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma
Damato, B. E., Dukes, J. D., Goodall, H., & Carvajal, R. D. (2019) · Cancers · doi:10.3390/cancers11070971 · Cited by 152 · see citing works
Immunotherapies and Combination Strategies for Immuno-Oncology
Barbari, C., Fontaine, T., Parajuli, P., Lamichhane, N., Jakubski, S., Lamichhane, P., & Deshmukh, R. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145009 · Cited by 142 · see citing works
Ligon, J. A., Choi, W., Cojocaru, G., Fu, W., Hsiue, E. H.-C., Oke, T. F., Siegel, N., Fong, M. H., Ladle, B., Pratilas, C. A., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001772 · Cited by 124 · see citing works
Dutta, S., Ganguly, A., Chatterjee, K., Spada, S., & Mukherjee, S. (2023) · Biology · doi:10.3390/biology12020218 · Cited by 134 · see citing works
Cancer Resistance to Immunotherapy: Comprehensive Insights with Future Perspectives
Said, S. S., & Ibrahim, W. N. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041143 · Cited by 127 · see citing works
Recent Advances in Molecular Mechanisms of Cancer Immunotherapy
Kciuk, M., Yahya, E. B., Mohamed, M. M. I., Rashid, S., Iqbal, M. O., Kontek, R., Abdulsamad, M. A., & Allaq, A. A. (2023) · Cancers · doi:10.3390/cancers15102721 · Cited by 128 · see citing works
Next-Generation Immunotherapy: Advancing Clinical Applications in Cancer Treatment
Garg, P. K., Pareek, S., Kulkarni, P., Horne, D., Salgia, R., & Singhal, S. S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216537 · Cited by 123 · see citing works
Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions
Pansy, K., Uhl, B., Krstić, J., Szmyra, M., Fechter, K., Santiso, A., Thüminger, L., Greinix, H., Kargl, J., Prochazka, K. T., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413311 · Cited by 110 · see citing works
Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?
Hosseinkhani, N., Derakhshani, A., Kooshkaki, O., Shadbad, M. A., Hajiasgharzadeh, K., Baghbanzadeh, A., Safarpour, H., Mokhtarzadeh, A., Brunetti, O., Yue, S. C., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218305 · Cited by 110 · see citing works
Immune system in cancer radiotherapy: Resistance mechanisms and therapy perspectives
Mortezaee, K., & Najafi, M. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103180 · Cited by 106 · see citing works
Saleh, R., Toor, S. M., Nair, V. S., & Elkord, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01469 · Cited by 103 · see citing works
Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects
Makaremi, S., Asadzadeh, Z., Hemmat, N., Baghbanzadeh, A., Sgambato, A., Ghorbaninezhad, F., Safarpour, H., Argentiero, A., Brunetti, O., Bernardini, R., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9091075 · Cited by 97 · see citing works
Wang, P., Chen, Y., Long, Q., Li, Q., Tian, J., Liu, T., Wu, Y., & Ding, Z. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002836 · Cited by 86 · see citing works
The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy
Russell, B. L., Sooklal, S. A., Malindisa, S. T., Daka, L. J., & Ntwasa, M. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.641428 · Cited by 84 · see citing works
Identification of new immune target and signaling for cancer immunotherapy
Narote, S., Desai, S. A., Patel, V. P., Deshmukh, R., Raut, N., & Dapse, S. (2025) · Cancer Genetics · doi:10.1016/j.cancergen.2025.03.004 · Cited by 92 · see citing works
Immunotherapy for colorectal cancer: Rational strategies and novel therapeutic progress
Rastin, F., Javid, H., Oryani, M. A., Rezagholinejad, N., Afshari, A. R., & Karimi‐Shahri, M. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111055 · Cited by 81 · see citing works
Ballesteros, P. Á., Chamorro, J., Román, M. S., Pozas, J., Santos, V. G. D., Granados, Á. R., Grande, E., Alonso‐Gordoa, T., & Molina‐Cerrillo, J. (2021) · Cancers · doi:10.3390/cancers13235981 · Cited by 69 · see citing works
Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy
Czajka‐Francuz, P., Prendes, M. J., Mankan, A. K., Quintana, Á., Pabla, S., Ramkissoon, S. H., Jensen, T. J., Peiró, S., Severson, E. A., Achyut, B. R., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1200646 · Cited by 69 · see citing works
Immune Checkpoint Molecules—Inherited Variations as Markers for Cancer Risk
Wagner, M., Jasek, M., & Karabon, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.606721 · Cited by 66 · see citing works
Yazdanifar, M., Zhou, R., Grover, P., Williams, C., Bose, M., Moore, L. J., Wu, S.-T., Chi, R., Maher, J., Dreau, D., et al. (2019) · Cells · doi:10.3390/cells8091070 · Cited by 65 · see citing works
Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer
Bianco, A., Perrotta, F., Barra, G., Malapelle, U., Rocco, D., & Palma, R. D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194931 · Cited by 63 · see citing works
Marcelis, L., Antoranz, A., Delsupehe, A.-M., Biesemans, P., Ferreiro, J. F., Debackere, K., Vandenberghe, P., Verhoef, G. E. G., Gheysens, O. S., Cattoretti, G., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02575-y · Cited by 63 · see citing works
Seven mysteries of LAG-3: a multi-faceted immune receptor of increasing complexity
Burnell, S. E. A., Capitani, L., MacLachlan, B. J., Mason, G. H., Gallimore, A., & Godkin, A. J. (2021) · Immunotherapy Advances · doi:10.1093/immadv/ltab025 · Cited by 62 · see citing works
Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites
Conway, J. W., Rawson, R. V., Lo, S., Ahmed, T., Vergara, I. A., Gide, T. N., Attrill, G. H., Carlino, M. S., Saw, R. P. M., Thompson, J. F., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004884 · Cited by 62 · see citing works
Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors
Ghaedrahmati, F., Esmaeil, N., & Abbaspour, M. (2022) · 癌症：英文版 · doi:10.1002/cac2.12394 · Cited by 57 · see citing works
NETosis as an oncologic therapeutic target: a mini review
Jaboury, S., Wang, K., O’Sullivan, K. M., Ooi, J. D., & Ho, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1170603 · Cited by 59 · see citing works
Immunotherapy in Testicular Germ Cell Tumors
Kaľavská, K., Schmidtova, S., Chovanec, M., & Mego, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.573977 · Cited by 57 · see citing works
Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors
Gravbrot, N., Gilbert-Gard, K., Mehta, P. P., Ghotmi, Y., Banerjee, M., Mazis, C. M., & Sundararajan, S. (2019) · Antibodies · doi:10.3390/antib8040051 · Cited by 56 · see citing works
Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes
Pesce, S., Trabanelli, S., Vito, C. D., Greppi, M., Obino, V., Guolo, F., Minetto, P., Bozzo, M., Calvi, M., Zaghi, E., et al. (2020) · Cancers · doi:10.3390/cancers12123504 · Cited by 53 · see citing works
Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy
Lee, E. S., Shin, J. M., Son, S., Ko, H., Um, W., Song, S. H., Lee, J. A., & Park, J. H. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801320 · Cited by 51 · see citing works
Kataoka, S., Manandhar, P., Lee, J., Workman, C. J., Banerjee, H., Szymczak-Workman, A. L., Kvorjak, M., Lohmueller, J. J., & Kane, L. (2021) · Science Signaling · doi:10.1126/scisignal.aba0717 · Cited by 51 · see citing works
Immune Checkpoints in Cancers: From Signaling to the Clinic
Pisibon, C., Ouertani, A., Bertolotto, C., Ballotti, R., & Chéli, Y. (2021) · Cancers · doi:10.3390/cancers13184573 · Cited by 49 · see citing works
TIMs, TAMs, and PS- antibody targeting: implications for cancer immunotherapy
Dayoub, A. S., & Brekken, R. A. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0521-5 · Cited by 49 · see citing works
Zhang, H., Zhao, W., Li, X., & He, Y. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s315998 · Cited by 49 · see citing works
Self-citationThe Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors
Moeckel, C. M., Bakhl, K., Georgakopoulos‐Soares, I., & Zaravinos, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076710 · Cited by 48 · see citing works
The role of immune checkpoints in antitumor response: a potential antitumor immunotherapy
Mejía-Guarnizo, L. V., Monroy-Camacho, P. S., Turizo-Smith, A. D., & Rodríguez-García, J. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1298571 · Cited by 48 · see citing works
Rawding, P. A., Bu, J., Wang, J., Kim, D., Drelich, A. J., Kim, Y. S., & Hong, S. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1752 · Cited by 47 · see citing works
Intratumoral Injection of Immunotherapeutics: State of the Art and Future Directions
Sheth, R. A., Wehrenberg-Klee, E. P., Patel, S. P., Brock, K. K., Fotiadis, N., & de Baère, T. (2024) · Radiology · doi:10.1148/radiol.232654 · Cited by 50 · see citing works
Human T cell glycosylation and implications on immune therapy for cancer
Bousser, E. D., Meuris, L., Callewaert, N., & Festjens, N. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1730658 · Cited by 45 · see citing works
Exhausted T cells hijacking the cancer-immunity cycle: Assets and liabilities
Brunell, A. E., Lahesmaa, R., Autio, A. K., & Thotakura, A. K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1151632 · Cited by 42 · see citing works
Zhang, L., Tian, S., Pei, M., Zhao, M., Wang, L., Jiang, Y., Yang, T., Zhao, J., Song, L., & Yang, X. (2019) · Oncology Reports · doi:10.3892/or.2019.7388 · Cited by 44 · see citing works
Molecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: An Update
Vukadin, S., Khaznadar, F., Kizivat, T., Včev, A., & Smolić, M. (2021) · Biomedicines · doi:10.3390/biomedicines9070835 · Cited by 46 · see citing works
Novel immune checkpoint targets: A promising therapy for cancer treatments
Patwekar, M. F., Sehar, N., Patwekar, F., Medikeri, A., Ali, S., Aldossri, R. M., & Rehman, M. U. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111186 · Cited by 44 · see citing works
Mycoplasma pneumoniae-related hepatitis in children
Poddighe, D. (2019) · Microbial Pathogenesis · doi:10.1016/j.micpath.2019.103863 · Cited by 44 · see citing works
Conciatori, F., Bazzichetto, C., Falcone, I., Ciuffreda, L., Ferretti, G., Vari, S., Ferraresi, V., Cognetti, F., & Milella, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155337 · Cited by 43 · see citing works
Saigí, M., Alburquerque-Béjar, J. J., & Sánchez‐Céspedes, M. (2019) · Oncogene · doi:10.1038/s41388-019-0855-x · Cited by 41 · see citing works
On the Horizon: Targeting Next-Generation Immune Checkpoints for Cancer Treatment
Tundo, G. R., Sbardella, D., Lacal, P. M., Graziani, G., & Marini, S. (2019) · Chemotherapy · doi:10.1159/000500902 · Cited by 40 · see citing works
Approaches to Enhance Natural Killer Cell-Based Immunotherapy for Pediatric Solid Tumors
Quamine, A. E., Olsen, M. R., Cho, M. M., & Capitini, C. M. (2021) · Cancers · doi:10.3390/cancers13112796 · Cited by 39 · see citing works
The basic biology of NK cells and its application in tumor immunotherapy
Jiang, P., Jing, S., Sheng, G., & Jia, F. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1420205 · Cited by 38 · see citing works
Toker, A., & Ohashi, P. S. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.05.001 · Cited by 37 · see citing works
Galectin-9: A Predictive Biomarker Negatively Regulating Immune Response in Glioma Patients
Liang, T., Wang, X., Wang, F., Feng, E., & You, G. (2019) · World Neurosurgery · doi:10.1016/j.wneu.2019.08.117 · Cited by 37 · see citing works
Bilemjian, V., Vlaming, M. R., Freile, J. Á., Huls, G. A., de Bruyn, M., & Bremer, E. (2022) · Cancers · doi:10.3390/cancers14133164 · Cited by 35 · see citing works
Nanomedicine for advanced cancer immunotherapy
Diep, Y. N., Kim, T. J., Cho, H., & Lee, L. P. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.10.004 · Cited by 34 · see citing works
Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer
Furukawa, K., Nagano, T., TACHIHARA, M. Y., Yamamoto, M., & Nishimura, Y. (2020) · Molecules · doi:10.3390/molecules25173900 · Cited by 36 · see citing works
Therapeutic Development of Immune Checkpoint Inhibitors
Wang, J., Yang, T., & Xu, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_23 · Cited by 34 · see citing works
The role of autophagy in colorectal cancer: Impact on pathogenesis and implications in therapy
Mahgoub, E., Taneera, J., Sulaiman, N. D., & Saber-Ayad, M. M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.959348 · Cited by 34 · see citing works
Abdel‐Rahman, S. A., Talagayev, V., Pach, S., Wolber, G., & Gabr, M. T. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00960 · Cited by 33 · see citing works
Wagener‐Ryczek, S., Schoemmel, M., Kraemer, M., Bruns, C. J., Schroeder, W., Zander, T., Gebauer, F., Alakus, H., Merkelbach‐Bruse, S., Buettner, R., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02475-w · Cited by 33 · see citing works
Checkpoint Markers and Tumor Microenvironment: What Do We Know?
Ephraim, R., Fraser, S., Nurgali, K., & Apostolopoulos, V. (2022) · Cancers · doi:10.3390/cancers14153788 · Cited by 33 · see citing works
Potential of Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer: Evidence to Date
McCusker, M. G., Orkoulas-Razis, D., & Mehra, R. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s196252 · Cited by 32 · see citing works
Granzyme B PET Imaging of Immune Checkpoint Inhibitor Combinations in Colon Cancer Phenotypes
Goggi, J., Tan, Y. X., Hartimath, S. V., Jieu, B., Hwang, Y. Y., Jiang, L., Boominathan, R., Cheng, P. K. C., Yuen, T. Y., Chin, H. X., et al. (2020) · Molecular Imaging and Biology · doi:10.1007/s11307-020-01519-3 · Cited by 31 · see citing works
TIM3+ cells in gastric cancer: clinical correlates and association with immune context
Chen, K., Gu, Y., Cao, Y., Fang, H., Lv, K., Liu, X., He, X., Wang, J., Lin, C., Liu, H., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01607-3 · Cited by 31 · see citing works
Ghorbaninezhad, F., Asadzadeh, Z., Masoumi, J., Mokhtarzadeh, A., Kazemi, T., Maleki, L. A., Shotorbani, S. S., Shadbad, M. A., Baghbanzadeh, A., Hemmat, N., et al. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120466 · Cited by 32 · see citing works
Tampaki, M., Ionas, E., Hadziyannis, E. S., Deutsch, M. J., Malagari, K. S., & Koskinas, J. S. (2020) · Cancers · doi:10.3390/cancers12010212 · Cited by 30 · see citing works
Regulatory T Cells in the Tumor Microenvironment
Dadey, R., Workman, C. J., & Vignali, D. A. A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-49270-0_6 · Cited by 30 · see citing works
The Glioma Immune Landscape: A Double-Edged Sword for Treatment Regimens
Mahajan, S., Schmidt, M. H. H., & Schumann, U. (2023) · Cancers · doi:10.3390/cancers15072024 · Cited by 29 · see citing works
Therapeutic vaccination immunomodulation: forming the basis of all cancer immunotherapy
Coventry, B. J. (2019) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/2515135519862234 · Cited by 28 · see citing works
The Immune Contexture of Liposarcoma and Its Clinical Implications
Resag, A., Toffanin, G., Benešová, I., Müller, L., Potkrajcic, V., Ozaniak, A., Lischke, R., Bartůňková, J., Rosato, A., Jöhrens, K., et al. (2022) · Cancers · doi:10.3390/cancers14194578 · Cited by 28 · see citing works
Ge, Y., Zhou, Q., Pan, F., & Wang, R. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s505539 · Cited by 27 · see citing works
Rapoport, B. L., Anderson, R., Cooksley, T., & Johnson, D. B. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05727-z · Cited by 27 · see citing works
Sarradin, V., Lusque, A., Filleron, T., Dalenc, F., & Franchet, C. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01437-4 · Cited by 27 · see citing works
Nanobodies Enhancing Cancer Visualization, Diagnosis and Therapeutics
Naidoo, D. B., & Chuturgoon, A. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189778 · Cited by 27 · see citing works
Schepisi, G., Gianni, C., Cursano, M. C., Gallá, V., Menna, C., Casadei, C., Bleve, S., Lolli, C., Martinelli, G., Rosti, G., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1118610 · Cited by 27 · see citing works
The miRNA and PD-1/PD-L1 signaling axis: an arsenal of immunotherapeutic targets against lung cancer
Yadav, R., Khatkar, R., Yap, K. C.-Y., Kang, C., Lyu, J., SINGH, R. K., Mandal, S., Mohanta, A., Lam, H. Y., Okina, E., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02182-1 · Cited by 27 · see citing works
Expression and Prognostic Value of the Immune Checkpoints Galectin-9 and PD-L1 in Glioblastomas
Knudsen, A. M., Rudkjøbing, S. J., Sørensen, M. D., Dahlrot, R. H., & Kristensen, B. W. (2021) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlab041 · Cited by 26 · see citing works
Epigenetic Perspective of Immunotherapy for Cancers
Keshari, S., Barrodia, P., & Singh, A. K. (2023) · Cells · doi:10.3390/cells12030365 · Cited by 25 · see citing works
Immune checkpoint inhibitors and cancer immunotherapy by aptamers: an overview
Kejamurthy, P., & Devi, K. T. R. (2023) · Medical Oncology · doi:10.1007/s12032-023-02267-4 · Cited by 25 · see citing works
Mestiri, S., El-Ella, D. M. A., Fernandes, Q., Bedhiafi, T., Almoghrabi, S., Akbar, S., Inchakalody, V. P., Assami, L., Anwar, S., Shahab Uddin, M. S., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116095 · Cited by 26 · see citing works
Khalaf, S., Toor, S. M., Murshed, K., Kurer, M. A., Ahmed, A., Nada, M. A., & Elkord, E. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108429 · Cited by 24 · see citing works
Hong, M. H., Shin, S., Shin, S. K., Kim, D. J., Zo, J. I., Shim, Y. M., Lee, S. E., Cho, B. C., Park, S. Y., Choi, Y., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-56828-7 · Cited by 23 · see citing works
Importance of the endometrial immune environment in endometrial cancer and associated therapies
van der Woude, H., Hally, K. E., Currie, M. J., Gasser, O., & Henry, C. E. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.975201 · Cited by 23 · see citing works
Cancer immunotherapy and its facilitation by nanomedicine
Sui, C., Wu, H., Li, X., Wang, Y., Wei, J., Yu, J., & Wu, X. (2024) · Biomarker Research · doi:10.1186/s40364-024-00625-6 · Cited by 23 · see citing works
Self-citationDuong, B. Q., Banskota, P., & Falchook, G. S. (2024) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-23-4 · Cited by 23 · see citing works
Immunotherapy – Strategies for Expanding Its Role in the Treatment of All Major Tumor Sites
Sanghera, C., & Sanghera, R. (2019) · Cureus · doi:10.7759/cureus.5938 · Cited by 22 · see citing works
The landscape of immune checkpoints expression in non-small cell lung cancer: a narrative review
Liu, Y., Chen, P., Wang, H., Wu, S., Zhao, S., He, Y., Zhou, C., & Hirsch, F. R. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1019 · Cited by 22 · see citing works
Self-citationZając, A. E., Król, S. K., Rutkowski, P. L., & Czarnecka, A. M. (2021) · Cancers · doi:10.3390/cancers13061317 · Cited by 22 · see citing works
CD137, an attractive candidate for the immunotherapy of lung cancer
Ye, L., Jia, K., Wang, L., Li, W., Chen, B., Liu, Y., Wang, H., Zhao, S., He, Y., & Zhou, C. (2020) · Cancer Science · doi:10.1111/cas.14354 · Cited by 22 · see citing works
Self-citationImmune Cell Landscape in Gastric Cancer
Yang, Y., He, W., Wang, Z., Wang, Y., Li, L., Lu, J., Tao, Y., Zhang, J., Fu, S., Wang, Z., et al. (2021) · BioMed Research International · doi:10.1155/2021/1930706 · Cited by 22 · see citing works
Brown, Z. J., Hewitt, D. B., & Pawlik, T. M. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2008355 · Cited by 21 · see citing works
CRISPR/Cas9 technology: towards a new generation of improved CAR-T cells for anticancer therapies
Ureña-Bailén, G., Lamsfus‐Calle, A., Daniel-Moreno, A., Raju, J., Schlegel, P., Seitz, C. M., Atar, D., Antony, J. S., Handgretinger, R., & Mezger, M. (2019) · Briefings in Functional Genomics · doi:10.1093/bfgp/elz039 · Cited by 23 · see citing works
Oncolytic HSV Vectors and Anti-Tumor Immunity
Glorioso, J. C., Cohen, J. B., Goins, W. F., Hall, B., Jackson, J. W., Kohanbash, G., Amankulor, N., Kaur, B., Caligiuri, M. A., Chiocca, E. A., et al. (2020) · Current Issues in Molecular Biology · doi:10.21775/cimb.041.381 · Cited by 21 · see citing works
- Authors
- He, Y., Cao, J., Zhao, C., Li, X., Zhou, C., & Hirsch, F.
- Affiliations
- Tongji University (CN)
- University of Colorado Anschutz (US)
- Corresponding author
- Zhou, Caicun
- Venue
- OncoTargets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2018-10
- Volume
- Volume 11
- Pages
- 7005-7009
- ISSN
- 1178-6930 (ISSN-L)
- PMC
- PMC6198883
- OpenAlex
- W2897230620
- Cited by
- 235
- References
- 59
- Citations by year
- 2026: 5 · 2025: 19 · 2024: 37 · 2023: 31 · 2022: 25 · 2021: 47 · 2020: 45 · 2019: 26
- FWCI
- 3.08
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- OncoTargets and Therapy (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- National Science Foundation
- National Natural Science Foundation of China (81802255)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- TIM-3, cancer immunotherapy, immune checkpoint, T cell exhaustion, anti-PD-1 therapy, CTLA-4, PD-1, monoclonal antibodies, clinical trials
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
